NCT02871791
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Participants with known brain metastases may be enrolled in this study, but certain conditions apply. See trial for details.
https://ClinicalTrials.gov/show/NCT02871791